Does China improve social welfare after implementing the national volume-based procurement?

被引:3
|
作者
Wang, Huan [1 ]
Huo, Ya-Tong [1 ]
Zhuang, Qian [1 ]
机构
[1] China Pharmaceut Univ, Sch Int Pharmaceut Business, Nanjing, Peoples R China
关键词
Chinese drug policy; national volume-based procurement; social welfare; consumer surplus; producer surplus; drug welfare;
D O I
10.3389/fphar.2023.1178026
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To explore the changes in social welfare before and after the implementation of the national volume-based procurement (NVBP). Explore whether the NVBP promotes the healthy development of manufacturers under the premise of benefiting patients. Then put forward relevant suggestions on how to effectively intervene the government in the pharmaceutical market.Methods: Starting with consumer surplus and producer surplus, social welfare was studied from the three perspectives of price, supply, and demand.Results: Consumer surplus was significantly increased, and the drug welfare of patients was significantly improved. The profits of the whole pharmaceutical industry have decreased but will increase in the future. The welfare of individual pharmaceutical enterprises varies. Overall social welfare has been significantly improved.Conclusion: The core purpose of the NVBP is to improve the medication welfare of patients, and through the increase of consumer surplus, it can affect the increase of producer surplus. Under such a linkage mechanism, the diversified linkage system of "price, demand, and supply" will achieve the effect of "1 + 1+1 > 3".
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Does China's national volume-based drug procurement policy promote or hinder pharmaceutical innovation?
    Li, Xiujuan
    Xu, Jiachun
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [2] Improving access to medicines and beyond: the national volume-based procurement policy in China
    Zhu, Zheng
    Wang, Quan
    Sun, Qiang
    Lexchin, Joel
    Yang, Li
    [J]. BMJ GLOBAL HEALTH, 2023, 8 (07):
  • [3] PRICE OFFERS IN VOLUME-BASED PROCUREMENT IN CHINA AND THEIR DETERMINANTS
    Sun, Y.
    Yang, L.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S477 - S477
  • [4] Administrative regulation-informed analysis of the developmental path of national volume-based procurement to improve drug accessibility in China
    Lu, Songxin
    Liu, Xiangdong
    Huang, Zhengzong
    Zhou, Zhiheng
    Feng, Zehua
    [J]. FRONTIERS IN PUBLIC HEALTH, 2024, 12
  • [5] National Volume-Based Procurement (NVBP) exclusively for insulin: towards affordable access in China and beyond
    Yuan, Jing
    Li, Minghui
    Jiang, Xiangxiang
    Lu, Zhiqiang Kevin
    [J]. BMJ GLOBAL HEALTH, 2024, 9 (01):
  • [6] Impact of China's National Volume-Based Procurement on Drug Procurement Price, Volume, and Expenditure: An Interrupted Time Series Analysis in Tianjin
    Zhao, Boya
    Wu, Jing
    [J]. INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT, 2023, 12 (01)
  • [7] CHALLENGE OR OPPORTUNITY? THE EXPANSION OF DRUG VOLUME-BASED PROCUREMENT IN CHINA
    Jin, J.
    He, Y.
    Mi, M.
    [J]. VALUE IN HEALTH, 2020, 23 : S136 - S136
  • [8] The cost of total hip arthroplasty: compare the hospitalization costs of national centralized procurement and national volume-based procurement
    Fan, Yongyong
    Xu, Qiang
    Jin, Gang
    Jiang, Lingjun
    Wang, Chenglong
    [J]. FRONTIERS IN PUBLIC HEALTH, 2024, 12
  • [9] Lowering drug prices and enhancing pharmaceutical affordability: an analysis of the national volume-based procurement (NVBP) effect in China
    Yuan, Jing
    Lu, Z. Kevinff
    Xiong, Xiaomo
    Jiang, Bin
    [J]. BMJ GLOBAL HEALTH, 2021, 6 (09):
  • [10] Impact of National Volume-Based Procurement on the Procurement Volumes and Spending for Antiviral Medications of Hepatitis B Virus
    Yuan, Jing
    Lu, Z. Kevin
    Xiong, Xiaomo
    Lee, Tai-Ying
    Huang, Huang
    Jiang, Bin
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13